Danske Bank: Acquisition of Icelandic wound care company will boost sales at Coloplast

However, the Danish bank sees less share price potential in the Coloplast stock than before.

by marketwire

Danske Bank has lowered its share price target for Coloplast to DKK 935 (USD 134.23) from DKK 1030 (USD 149.16), citing higher weighted average cost of capital and a larger number of shares after the almost DKK 9bn (USD 1.29bn) acquisition of the Icelandic wound care company Kerecis.

Already a subscriber?Log in here

Read the whole article

Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

With your free trial you get:

Access all locked articles
Receive our daily newsletters
Access our app

Get full access for you and your coworkers

Start a free company trial today

Coloplast bags DKK 9.2bn through rights issue
For subscribers
Coloplast expects to grow Icelandic acquisition manifold in a few years
For subscribers
After new billion-dollar acquisition: Coloplast CEO rules out more acquisitions for two years
For subscribers

Sign up for our newsletter

Stay ahead of development by receiving our newsletter on the latest sector knowledge.

Newsletter terms

Front page now

Pharma & biotech

Investment bank: Novo Nordisk's patent victory is a small victory as price negotiations loom

The market’s attention is more focused on public health insurance Medicare’s new price negotiations under the so-called Inflation Reduction Act.

For subscribers

Pharma & biotech

FDA approves Novo Nordisk drug to treat rare condition

For subscribers

Fujifilm Diosynth Biotechnologies' factory in Hillerød, Denmark. | Foto: Liselotte Plenov / Fotorummet / Pr

Pharma & biotech

Fujifilm expands management with former Leo executive

For subscribers

Foto: Andrew Kelly/Reuters/Ritzau Scanpix

Pharma & biotech

Low share price may knock Galecto off the stock exchange

For subscribers

Pharma & biotech

Snack maker keeps an eye on Novo Nordisk's obesity drug

Foto: Yuriko Nakao/Reuters/Ritzau Scanpix

Medtech

Olympus appoints new chief medical officer

For subscribers

Novo Nordisk's semaglutide to be studied for positive effect on alcoholics
Previous studies have shown that alcohol cravings disappeared when people were treated with GLP-1 agonist exanatide.
For subscribers
Vaccine breakthrough behind mRNA shots wins Nobel Prize
The two scientists will share the 11 million-krona ( USD 1 million) award, the Nobel Assembly at the Karolinska Institutet in Stockholm said in a statement Monday.
For subscribers
WS Audiology hires new chief technology officer from car manufacturer
He succeeds chief research & development officer Stefan Menzl, who is stepping down after six years.
For subscribers
Novo Nordisk files lawsuit against US authorities ahead of price negotiation
The litigation is the latest in a long line of industry lawsuits related to price negotiations.
For subscribers
FDA rejects atopic dermatitis drug lebrikizumab
Eli Lilly had expected a launch this year.
For subscribers
FDA updates Novo Nordisk's Ozempic drug label with side effect alert
The diabetes drug might cause a potentially fatal intestinal blockage, the authorities warn.
For subscribers

FDA approves Novo Nordisk drug to treat rare condition

The marketing authorization applies to children and adolescents aged 9 years and older, as well as adults with ”relatively” preserved kidney functions.

For subscribers

Pharma & biotech